Related Experiment Video
Updated: Apr 19, 2026

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept
Inês Brás Marques1, Gavin Giovannoni2, Monica Marta3
1Queen Mary University London, Blizard Institute, 4 Newark Street, London, E1 1AT, UK. i.marques@qmul.ac.uk.
Background:
Several disorders may present with mononeuritis multiplex and the etiological diagnosis can be challenging.
Case Presentation:
We report a 42 year-old female who presented with severe lower limb neuropathic pain, asymmetric weakness and sensory impairment and was diagnosed with mononeuritis multiplex. Biopsy showed a granulomatous vasculitic process with eosinophils, scarce granulomata and axonal neuropathy and granulomatosis with poliangiitis was assumed. Steroids, cyclophosphamide, alemtuzumab, azathioprine, mycophenolate mofetil and rituximab were used, all with transient and insufficient response. Skin biopsy performed in a further exacerbation allowed sarcoidosis diagnosis. Infliximab and, later, adalimumab induced good clinical and laboratorial response, but neutralizing antibodies developed to both drugs, so etanercept was tried with good clinical response.
Conclusions:
To the best of our knowledge, this is the first report of sarcoidosis successfully treated with etanercept. This drug may be considered in refractory sarcoidosis after other TNF-α inhibitors failure, having the advantage of not being associated with neutralizing antibodies development.
Related Concept Videos
Multiple Sclerosis l: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
